At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 4 enrolled
Drug / intervention
AZ6244drug
Likely dose
AZ6244 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer
In Brief
A Early Phase 1 clinical trial evaluating AZ6244 for Breast Cancer. Completed, enrolled 4 participants across 1 site.
Detailed Summary
If AZD6244 is able to increase ER expression in ER-negative/low cancers then it may be possible to effectively use hormonal therapy in these patients resulting in improved outcomes. The investigators propose a single-arm Simon two-step study to examine whether treatment with AZD6244 will result in increased ER expression in ER-negative/low primary breast tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
Early Ph 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedMar 2011
Primary CompletionApr 2014
TodayJul 2026
First PostedMar 11, 2011
Enrollment StartFeb 1, 2011
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 15.3 years ago
Interventions
AZ6244drug
AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15